Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.
Industries
Life Sciences
We bring clarity to complex challenges.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Engagements
- 01Evaluating unintended impacts of the IRA’s Medicare Drug Price Negotiation Program on small and large molecule medicinesA leading pharmaceutical company sought support from CRA Life Sciences experts in analyzing the patient, health system, and innovation implications of the IRA'sView engagement
- 02Developing an evidence-based framework for sustainable NCCP funding and address global disparities in implementation and outcomesA leading pharmaceutical company sought CRA Life Sciences experts to gain a deeper understanding of how governments plan and finance national cancer strategiesView engagement
- 03Mapping and assessing national impacts of JCAs across EuropeCRA Life Science experts were retained by a client to provide support on the impact of the EU HTA regulation and the associated JCAs on national HTA systems.View engagement
Contact a Life Sciences expert.
See all Life Sciences expertsRecent events
Sex and Gender in the Patient Journey: Lessons from Alzheimer’s Disease Webinar
Tunahan Kirabali is a speaker during the webinar about sex and gender differences in the Alzheimer’s patient journey highlighting implications for clinical...
InformaConnect: CompLaw Pharma
CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as...